Press release
Metastatic Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics
Discover the latest drugs and treatment options in the Metastatic Renal Cell Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Renal Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
* July 2024:- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
* July 2024:- Hospital das Clinicas de Ribeirao Preto- The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
* DelveInsight's Metastatic Renal Cell Carcinoma Pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
* The leading Metastatic Renal Cell Carcinoma Companies such as AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
* Promising Metastatic Renal Cell Carcinoma Therapies such as Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.
Stay ahead with the most recent pipeline outlook for Metastatic Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Renal Cell Carcinoma Treatment [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Renal Cell Carcinoma Emerging Drugs Profile
* Olaparib: AstraZeneca
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
* Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
* TP-1454: Sumitomo Dainippon Pharma
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.
Explore groundbreaking therapies and clinical trials in the Metastatic Renal Cell Carcinoma Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Renal Cell Carcinoma Drugs [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Unveil the future of Metastatic Renal Cell Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
* Coverage- Global
* Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
* Metastatic Renal Cell Carcinoma Therapies- Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.
* Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Metastatic Renal Cell Carcinoma therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Renal Cell Carcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Renal Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Renal Cell Carcinoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atezolizumab: Genentech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Olaparib: AstraZeneca
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TP-1454: Sumitomo Dainippon Pharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Renal Cell Carcinoma Key Companies
* Metastatic Renal Cell Carcinoma Key Products
* Metastatic Renal Cell Carcinoma- Unmet Needs
* Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
* Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
* Metastatic Renal Cell Carcinoma Analyst Views
* Metastatic Renal Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-renal-cell-carcinoma-pipeline-2024-astrazeneca-genentech-sumitomo-dainippon-pharma-allogene-therapeutics-nektar-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics here
News-ID: 3571076 • Views: …
More Releases from ABNewswire
Pie Launches HMRC-Recognised Tax Return Software for MTD UK 2026
Pie Money Limited has launched its HMRC-recognised self assessment software, positioning Pie as the UK's best tax return solution ahead of Making Tax Digital 2026. With real-time tax calculations, smart bookkeeping, and seamless HMRC integration, Pie helps freelancers, contractors, and small businesses file taxes with confidence, accuracy, and ease.
Dublin, Ireland - 27 August, 2025 - Pie Money Limited, the fintech innovator behind Pie.tax, has today announced the expansion of its…
How Trapping USA Protects Richardson, TX, Families and Pets Through Safe Pest Co …
Trapping USA provides safe and effective pest control in Richardson, TX, using eco-friendly methods that protect families, pets, and the environment from harmful pests.
Richardson, TX - As Richardson, TX, continues to grow, so does the need for effective pest control services that protect both homes and families. Trapping USA is at the forefront of delivering pest control services that prioritize safety, ensuring families and pets remain safe while receiving top-tier…
Pie Launches AI-Powered Upgrade to the Best Tax Return Software in the UK 2025
Designed to provide real-time tax advice, automatic error checks, and personalised filing insights, the AI Assistant strengthens Pie's position as the best self assessment software in the UK. "Tax doesn't need to be complicated," said Tommy McNally, Founder of Pie Money Limited. "With our AI Assistant, we've taken the guesswork out of self assessment.
Dublin, Ireland - 27 August, 2025 - Pie Money Limited, creators of Pie.tax, today announced the launch…
Sydney Tiling Pro Celebrates 17 Years of Excellence as Professional Tilers
Sydney Tiling Pro, a trusted name in residential and commercial tiling across the city, proudly announces its 17th anniversary. Since 2008, the company has been delivering precision craftsmanship, reliable service, and transparent pricing, earning the trust of both homeowners and businesses, and often being referred to as one of the best tilers in Sydney [https://sydneytilingpro.com/] and the surrounding areas.
Over the past 17 years, Sydney Tiling Pro has transformed properties with…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
